SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SpringWorks Therapeutics (SWTX), a commercial-stage biopharmaceutical company specializing in severe rare diseases and cancer, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Chief Executive Officer Saqib Islam will deliver a presentation on Monday, January 13, 2025, at 11:15 a.m. PT.
The presentation will be accessible via live webcast through the Events & Presentations page in the Investors & Media section of SpringWorks' website. Interested parties can view a replay of the presentation for a time following the conference through the company's website at ir.springworkstx.com.
SpringWorks Therapeutics (SWTX), un'azienda biofarmaceutica in fase commerciale specializzata in malattie rare gravi e cancro, ha annunciato la sua partecipazione al 43° Annual J.P. Morgan Healthcare Conference. L'Amministratore Delegato Saqib Islam presenterà un intervento lunedì 13 gennaio 2025, alle 11:15 ora del Pacifico.
La presentazione sarà accessibile tramite webcast live nella pagina Eventi e Presentazioni della sezione Investitori e Media del sito web di SpringWorks. Le parti interessate potranno rivedere la presentazione per un periodo di tempo dopo la conferenza sul sito dell'azienda all'indirizzo ir.springworkstx.com.
SpringWorks Therapeutics (SWTX), una compañía biofarmacéutica en etapa comercial especializada en enfermedades raras severas y cáncer, ha anunciado su participación en la 43ª Conferencia Anual de Salud J.P. Morgan. El Director Ejecutivo Saqib Islam realizará una presentación el lunes 13 de enero de 2025, a las 11:15 a.m. PT.
La presentación será accesible a través de una transmisión en vivo en la página de Eventos y Presentaciones en la sección de Inversores y Medios del sitio web de SpringWorks. Las partes interesadas podrán ver una repetición de la presentación por un tiempo después de la conferencia en el sitio web de la empresa en ir.springworkstx.com.
春作 치료제(SpringWorks Therapeutics, SWTX), 심각한 희귀 질병 및 암을 전문으로 하는 상업 단계의 생명공학 회사가 제43회 JP 모건 헬스케어 회의에 참여한다고 발표했습니다. CEO인 사키브 이슬람(Saqib Islam)은 2025년 1월 13일 월요일, 태평양 표준시 기준 오전 11시 15분에 발표를 진행할 예정입니다.
발표는 SpringWorks 웹사이트의 투자자 및 미디어 섹션 내 이벤트 및 발표 페이지를 통해 생중계로 시청할 수 있습니다. 관심 있는 분들은 회사 웹사이트인 ir.springworkstx.com에서 회의 후 일정 기간 동안 재생 replay를 볼 수 있습니다.
SpringWorks Therapeutics (SWTX), une entreprise bio-pharmaceutique en phase commerciale spécialisée dans les maladies rares graves et le cancer, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan sur la Santé. Le PDG Saqib Islam fera une présentation le lundi 13 janvier 2025, à 11h15 PT.
La présentation sera accessible en direct via un webcast sur la page Événements & Présentations dans la section Investisseurs & Médias du site Web de SpringWorks. Les parties intéressées pourront visionner une rediffusion de la présentation pendant un certain temps après la conférence sur le site de l'entreprise à l'adresse ir.springworkstx.com.
SpringWorks Therapeutics (SWTX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf schwere seltene Erkrankungen und Krebs spezialisiert hat, hat seine Teilnahme an der 43. Jahrestagung der J.P. Morgan Healthcare Conference angekündigt. CEO Saqib Islam wird am Montag, den 13. Januar 2025, um 11:15 Uhr PT eine Präsentation halten.
Die Präsentation wird über einen Live-Webcast auf der Seite „Veranstaltungen & Präsentationen“ im Bereich „Investoren & Medien“ der Website von SpringWorks zugänglich sein. Interessierte können die Präsentation für eine gewisse Zeit nach der Konferenz auf der Unternehmenswebsite unter ir.springworkstx.com wieder ansehen.
- None.
- None.
STAMFORD, Conn., Jan. 03, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 11:15 a.m. PT.
To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference.
About SpringWorks Therapeutics
SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. OGSIVEO® (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment, is the Company’s first FDA-approved therapy. SpringWorks also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. In addition to its wholly owned programs, SpringWorks has also entered into multiple collaborations with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients in need.
For more information, visit www.springworkstx.com and follow @SpringWorksTx on X (formerly Twitter), LinkedIn, and YouTube.
Contacts:
Investors
investors@springworkstx.com
Media
media@springworkstx.com
FAQ
When is SpringWorks Therapeutics (SWTX) presenting at the J.P. Morgan Healthcare Conference 2025?
How can investors watch SpringWorks Therapeutics' (SWTX) J.P. Morgan Healthcare Conference presentation?
Will there be a replay available of SpringWorks Therapeutics' (SWTX) J.P. Morgan presentation?
What therapeutic areas does SpringWorks Therapeutics (SWTX) focus on?
